Safety and Efficacy of Glucagon‐Like Peptide‐1 Receptor Agonists Use in Elderly People With Obesity—A Meta‐Analysis
Obesity · 2026-09 · 34 (S2) · 25-35
DOI: 10.1002/oby.70098 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Obesity, online erschienen am 04.02.2026. Verfasst von Inês Rego de Figueiredo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Multidisciplinary Unit of Bariatric and Metabolic Surgery, Curry Cabral Hospital, Unidade Local de Saúde São José, Centro Clínico Académico de Lisboa…. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Obesity, Hypoglycemic Agents. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
This meta‐analysis evaluates the safety and efficacy of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) for the treatment of older adults with obesity compared to younger individuals.
Methods
A systematic review was conducted following PRISMA guidelines (PROSPERO CRD420251074381). PubMed, Embase, and Scopus were searched until May 17, 2025, for randomized controlled trials and observational studies assessing GLP‐1 RA in adults ≥ 65 years with obesity with or without type 2 diabetes. Random effects meta‐analyses calculated the log odds ratios (LOR) for dichotomous outcomes and the mean differences (MD) for continuous outcomes, with equivalence testing via two one‐sided tests (TOST) and meta‐regression for baseline adjustments.
Results
Five studies involving 1229 participants were included. No significant difference in serious adverse events was found between older and younger adults (pooled LOR: 0.06, p = 0.9). Older adults had a trend toward lower frequency of nausea (LOR: −0.44, p = 0.06) but higher incidence of constipation (LOR: 0.72, p = 0.02) and hypoglycemia (LOR: 0.97, p < 0.001). Efficacy in metabolic and weight control was comparable. Additionally, one study suggested that liraglutide could reduce fat mass without worsening sarcopenia.
Conclusions
GLP‐1 RA therapy seems to be safe and effective in older adults with obesity, achieving similar effects on weight loss and glycemic control as in younger individuals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Multidisciplinary Unit of Bariatric and Metabolic Surgery, Curry Cabral Hospital, Unidade Local de Saúde São José, Centro Clínico Académico de Lisboa, Lisbon, Portugal.
- Egas Moniz School of Health and Science, Almada, Portugal.
- NOVA Medical School/Faculdade de Ciencias Medicas, New University of Lisbon, Lisbon, Portugal.
- Department of Nutrition, Curry Cabral Hospital, Unidade Local de Saúde São José, Centro Clínico Académico de Lisboa, Lisbon, Portugal.
- Department of Internal Medicine, Hospital Garcia de Orta, Unidade Local de Saúde Almada-Seixal, Almada, Portugal.
- Department of Endocrinology, Diabetes, and Metabolism, Curry Cabral Hospital, Unidade Local de Saúde São José, Centro Clínico Académico de Lisboa, Lisbon, Portugal.
ORCID-Profile: Inês Rego de Figueiredo
Zitieren
APA
Rego de Figueiredo, I., Simas, F. S., Ghiletchi, A., Oliveira Torres, J., & Silva-Nunes, J. (2026). Safety and Efficacy of Glucagon‐Like Peptide‐1 Receptor Agonists Use in Elderly People With Obesity—A Meta‐Analysis. Obesity, 34(S2), 25-35. https://doi.org/10.1002/oby.70098
Vancouver
Rego de Figueiredo I, Simas FS, Ghiletchi A, Oliveira Torres J, Silva-Nunes J. Safety and Efficacy of Glucagon‐Like Peptide‐1 Receptor Agonists Use in Elderly People With Obesity—A Meta‐Analysis. Obesity. 2026;34(S2):25-35. doi:10.1002/oby.70098
BibTeX
@article{RegodeFigueiredo2026,
author = {Rego de Figueiredo, Inês and Simas, Filipa Sofia and Ghiletchi, Angela and Oliveira Torres, João and Silva-Nunes, José},
title = {Safety and Efficacy of Glucagon‐Like Peptide‐1 Receptor Agonists Use in Elderly People With Obesity—A Meta‐Analysis},
journal = {Obesity},
year = {2026},
volume = {34},
number = {S2},
pages = {25--35},
doi = {10.1002/oby.70098}
}
EUVIMED